-
1
-
-
84894107349
-
New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
-
Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
-
(2014)
Curr Opin Immunol
, vol.27
, pp. 16-25
-
-
Mittal, D.1
Gubin, M.M.2
Schreiber, R.D.3
Smyth, M.J.4
-
2
-
-
84886698315
-
Innate and adaptive immune cells in the tumor microenvironment
-
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-1022.
-
(2013)
Nat Immunol
, vol.14
, pp. 1014-1022
-
-
Gajewski, T.F.1
Schreiber, H.2
Fu, Y.X.3
-
4
-
-
84864140772
-
Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death
-
Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 2012;33:406-412.
-
(2012)
Trends Immunol
, vol.33
, pp. 406-412
-
-
Lopez, J.A.1
Brennan, A.J.2
Whisstock, J.C.3
Voskoboinik, I.4
Trapani, J.A.5
-
5
-
-
84944277572
-
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
-
Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015;4:e1016700.
-
(2015)
Oncoimmunology
, vol.4
-
-
Wu, A.A.1
Drake, V.2
Huang, H.S.3
Chiu, S.4
Zheng, L.5
-
6
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
-
(2003)
N Engl J Med
, vol.348
, pp. 203-213
-
-
Zhang, L.1
-
7
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
-
8
-
-
84928759208
-
Adoptive cell transfer as personalized immunotherapy for human cancer
-
Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-68.
-
(2015)
Science
, vol.348
, pp. 62-68
-
-
Rosenberg, S.A.1
Restifo, N.P.2
-
9
-
-
84943143291
-
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology
-
Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015;49:907-937.
-
(2015)
Ann Pharmacother
, vol.49
, pp. 907-937
-
-
Barbee, M.S.1
Ogunniyi, A.2
Horvat, T.Z.3
Dang, T.O.4
-
10
-
-
84937707232
-
Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street
-
Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol 2015;195:755-761.
-
(2015)
J Immunol
, vol.195
, pp. 755-761
-
-
Barrett, D.M.1
Grupp, S.A.2
June, C.H.3
-
11
-
-
84962948025
-
Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials
-
[E-pub ahead of print].
-
Zhu Y, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol 2015 [E-pub ahead of print].
-
(2015)
Eur J Haematol
-
-
Zhu, Y.1
-
12
-
-
84936934575
-
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
-
Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Exp Opin Biol Ther 2015;15:1093-1099.
-
(2015)
Exp Opin Biol Ther
, vol.15
, pp. 1093-1099
-
-
Stieglmaier, J.1
Benjamin, J.2
Nagorsen, D.3
-
13
-
-
0021832361
-
Hybrid antibodies can target sites for attack by T cells
-
Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-631.
-
(1985)
Nature
, vol.314
, pp. 628-631
-
-
Staerz, U.D.1
Kanagawa, O.2
Bevan, M.J.3
-
14
-
-
79955662260
-
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
-
Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011;317:1255-1260.
-
(2011)
Exp Cell Res
, vol.317
, pp. 1255-1260
-
-
Nagorsen, D.1
Baeuerle, P.A.2
-
15
-
-
28944434529
-
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
-
Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-771.
-
(2006)
Mol Immunol
, vol.43
, pp. 763-771
-
-
Offner, S.1
Hofmeister, R.2
Romaniuk, A.3
Kufer, P.4
Baeuerle, P.A.5
-
16
-
-
64649103924
-
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
-
Haas C, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-453.
-
(2009)
Immunobiology
, vol.214
, pp. 441-453
-
-
Haas, C.1
-
17
-
-
58549109813
-
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
-
d'Argouges S, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-473.
-
(2009)
Leuk Res
, vol.33
, pp. 465-473
-
-
d'Argouges, S.1
-
18
-
-
0343415665
-
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
-
Loffler A, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-2103.
-
(2000)
Blood
, vol.95
, pp. 2098-2103
-
-
Loffler, A.1
-
19
-
-
28744445538
-
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
-
Brischwein K, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-1143.
-
(2006)
Mol Immunol
, vol.43
, pp. 1129-1143
-
-
Brischwein, K.1
-
20
-
-
37349123501
-
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
-
Brischwein K, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807.
-
(2007)
J Immunother
, vol.30
, pp. 798-807
-
-
Brischwein, K.1
-
21
-
-
0037143806
-
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
-
Dreier T, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-697.
-
(2002)
Int J Cancer
, vol.100
, pp. 690-697
-
-
Dreier, T.1
-
22
-
-
0031569465
-
Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity
-
Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 1997;158:3965-3970.
-
(1997)
J Immunol
, vol.158
, pp. 3965-3970
-
-
Mack, M.1
Gruber, R.2
Schmidt, S.3
Riethmuller, G.4
Kufer, P.5
-
23
-
-
84902674948
-
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia
-
Friedrich M, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014;13:1549-1557.
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 1549-1557
-
-
Friedrich, M.1
-
24
-
-
34447643439
-
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
-
Brandl C, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-1563.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 1551-1563
-
-
Brandl, C.1
-
25
-
-
78149437871
-
Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110
-
Kischel R, Hausmann S, Baeuerle P, Kufer P. Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. Cancer Res 2009;69:3252.
-
(2009)
Cancer Res
, vol.69
, pp. 3252
-
-
Kischel, R.1
Hausmann, S.2
Baeuerle, P.3
Kufer, P.4
-
26
-
-
84913600520
-
Emerging roles of regulatory T cells in tumour progression and metastasis
-
Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014;33:1025-1041.
-
(2014)
Cancer Metastasis Rev
, vol.33
, pp. 1025-1041
-
-
Halvorsen, E.C.1
Mahmoud, S.M.2
Bennewith, K.L.3
-
27
-
-
84969383282
-
Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody
-
Münz M, et al. Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody. Cancer Res 2012;72:4841.
-
(2012)
Cancer Res
, vol.72
, pp. 4841
-
-
Münz, M.1
-
28
-
-
84929868959
-
Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients
-
Duell J, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood 2014;124:2291.
-
(2014)
Blood
, vol.124
, pp. 2291
-
-
Duell, J.1
-
29
-
-
17644385543
-
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
-
Hoffmann P, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104.
-
(2005)
Int J Cancer
, vol.115
, pp. 98-104
-
-
Hoffmann, P.1
-
30
-
-
79957450612
-
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
-
Raponi S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-1107.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 1098-1107
-
-
Raponi, S.1
-
31
-
-
0037851832
-
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
-
Loffler A, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-909.
-
(2003)
Leukemia
, vol.17
, pp. 900-909
-
-
Loffler, A.1
-
32
-
-
0037446782
-
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct
-
Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397-4402.
-
(2003)
J Immunol
, vol.170
, pp. 4397-4402
-
-
Dreier, T.1
-
33
-
-
33645007038
-
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
-
Schlereth B, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006;55:503-514.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 503-514
-
-
Schlereth, B.1
-
35
-
-
84927667667
-
Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL)
-
Hijazi Y, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J Clin Oncol 2013;31:3051.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3051
-
-
Hijazi, Y.1
-
36
-
-
84929896570
-
Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
-
Schub A, et al. Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). J Clin Oncol 2013;31:7020.
-
(2013)
J Clin Oncol
, vol.31
, pp. 7020
-
-
Schub, A.1
-
37
-
-
49649120397
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
-
Bargou R, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977.
-
(2008)
Science
, vol.321
, pp. 974-977
-
-
Bargou, R.1
-
38
-
-
84925461494
-
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
-
Zugmaier G, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244.
-
(2014)
Blood Cancer J
, vol.4
, pp. 244
-
-
Zugmaier, G.1
-
39
-
-
84863522243
-
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
-
Klinger M, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-6233.
-
(2012)
Blood
, vol.119
, pp. 6226-6233
-
-
Klinger, M.1
-
40
-
-
79959312575
-
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
-
Topp MS, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-2498.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2493-2498
-
-
Topp, M.S.1
-
42
-
-
79958043675
-
-
Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at:
-
Howlader N, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/
-
SEER Cancer Statistics Review, 1975-2012
-
-
Howlader, N.1
-
43
-
-
79952095577
-
Modern therapy of acute lymphoblastic leukemia
-
Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-543.
-
(2011)
J Clin Oncol
, vol.29
, pp. 532-543
-
-
Bassan, R.1
Hoelzer, D.2
-
44
-
-
84863772728
-
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group
-
Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012;30:1663-1669.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1663-1669
-
-
Hunger, S.P.1
-
45
-
-
61849122810
-
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century
-
Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113:1408-1411.
-
(2009)
Blood
, vol.113
, pp. 1408-1411
-
-
Pulte, D.1
Gondos, A.2
Brenner, H.3
-
47
-
-
78650083131
-
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
-
Kantarjian HM, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-5574.
-
(2010)
Cancer
, vol.116
, pp. 5568-5574
-
-
Kantarjian, H.M.1
-
48
-
-
84875716409
-
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
-
O'Brien S, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31:676-683.
-
(2013)
J Clin Oncol
, vol.31
, pp. 676-683
-
-
O'Brien, S.1
-
49
-
-
84865709936
-
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
-
Gokbuget N, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-1876.
-
(2012)
Blood
, vol.120
, pp. 1868-1876
-
-
Gokbuget, N.1
-
50
-
-
84916639631
-
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
-
Topp MS, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134-4140.
-
(2014)
J Clin Oncol
, vol.32
, pp. 4134-4140
-
-
Topp, M.S.1
-
51
-
-
84871491706
-
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
-
Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-5187.
-
(2012)
Blood
, vol.120
, pp. 5185-5187
-
-
Topp, M.S.1
-
52
-
-
84929877546
-
®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)
-
®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood 2014;124:379.
-
(2014)
Blood
, vol.124
, pp. 379
-
-
Goekbuget, N.1
-
53
-
-
78651290248
-
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
-
Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-184.
-
(2011)
Leukemia
, vol.25
, pp. 181-184
-
-
Handgretinger, R.1
Zugmaier, G.2
Henze, G.3
Kreyenberg, H.4
Lang, P.5
von Stackelberg, A.6
-
54
-
-
84926099033
-
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
-
Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66.
-
(2015)
Lancet Oncol
, vol.16
, pp. 57-66
-
-
Topp, M.S.1
-
55
-
-
84903632926
-
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
-
Schlegel P, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014;99:1212-1219.
-
(2014)
Haematologica
, vol.99
, pp. 1212-1219
-
-
Schlegel, P.1
-
56
-
-
9444268741
-
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
-
Stone MJ, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996;88:1188-1197.
-
(1996)
Blood
, vol.88
, pp. 1188-1197
-
-
Stone, M.J.1
-
57
-
-
84864544136
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
-
Younes A, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-2782.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2776-2782
-
-
Younes, A.1
-
58
-
-
84863337890
-
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
-
Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-2720.
-
(2012)
Blood
, vol.119
, pp. 2709-2720
-
-
Kochenderfer, J.N.1
-
59
-
-
84876005284
-
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
-
177ra138
-
Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra138.
-
(2013)
Sci Transl Med
, vol.5
-
-
Brentjens, R.J.1
-
60
-
-
84929875600
-
Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin's lymphoma
-
Goebeler ME, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin's lymphoma. Hematol Oncol 2013;31:151-200.
-
(2013)
Hematol Oncol
, vol.31
, pp. 151-200
-
-
Goebeler, M.E.1
-
61
-
-
84969405509
-
Blinatumomab treatment in relapsed/refractory diffuse large B-cell lymphoma in an open-label, phase 2 study: safety, efficacy and late responses
-
Viardot A, et al. Blinatumomab treatment in relapsed/refractory diffuse large B-cell lymphoma in an open-label, phase 2 study: safety, efficacy and late responses. Hematol Oncol 2015;33:181-243.
-
(2015)
Hematol Oncol
, vol.33
, pp. 181-243
-
-
Viardot, A.1
-
62
-
-
0035863406
-
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
-
Vose JM, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
-
(2001)
J Clin Oncol
, vol.19
, pp. 389-397
-
-
Vose, J.M.1
-
64
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
-
Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
-
(2002)
N Engl J Med
, vol.346
, pp. 1937-1947
-
-
Rosenwald, A.1
-
65
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
-
(2004)
Blood
, vol.103
, pp. 275-282
-
-
Hans, C.P.1
-
66
-
-
27644488026
-
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
-
Bea S, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-3190.
-
(2005)
Blood
, vol.106
, pp. 3183-3190
-
-
Bea, S.1
-
67
-
-
53749093794
-
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
-
Fu K, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4587-4594
-
-
Fu, K.1
-
68
-
-
0036739436
-
Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
-
Spaepen K, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
-
(2002)
Ann Oncol
, vol.13
, pp. 1356-1363
-
-
Spaepen, K.1
-
69
-
-
84940040980
-
Positron emission tomography (PET) guided therapy of aggressive lymphomas - a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial)
-
Duehrsen U, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas - a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood 2014;124:391.
-
(2014)
Blood
, vol.124
, pp. 391
-
-
Duehrsen, U.1
-
70
-
-
77957965500
-
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
-
Gisselbrecht C, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4184-4190
-
-
Gisselbrecht, C.1
-
71
-
-
84934925868
-
Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928)
-
van Imhoff GW, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928). Blood 2014;124:630.
-
(2014)
Blood
, vol.124
, pp. 630
-
-
van Imhoff, G.W.1
-
72
-
-
84902316289
-
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
-
Feldman T, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol 2014;166:77-83.
-
(2014)
Br J Haematol
, vol.166
, pp. 77-83
-
-
Feldman, T.1
-
73
-
-
84925587926
-
Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
-
Lesokhin AM, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014;124:291.
-
(2014)
Blood
, vol.124
, pp. 291
-
-
Lesokhin, A.M.1
-
74
-
-
84922348765
-
Current therapeutic strategies and new treatment paradigms for follicular lymphoma
-
Kritharis A, Sharma J, Evens AM. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Cancer Treat Res 2015;165:197-226.
-
(2015)
Cancer Treat Res
, vol.165
, pp. 197-226
-
-
Kritharis, A.1
Sharma, J.2
Evens, A.M.3
-
75
-
-
84930701624
-
Treatment of chronic lymphocytic leukaemia, where are we heading?
-
O'Brien SMVIII. Treatment of chronic lymphocytic leukaemia, where are we heading? Hematol Oncol 2015;33(Suppl 1):46-49.
-
(2015)
Hematol Oncol
, vol.33
, pp. 46-49
-
-
O'Brien, S.M.V.1
-
76
-
-
54049158129
-
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
-
O'Shea D, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126-3129.
-
(2008)
Blood
, vol.112
, pp. 3126-3129
-
-
O'Shea, D.1
-
77
-
-
84933673408
-
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
-
Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015;16:541-549.
-
(2015)
Lancet Oncol
, vol.16
, pp. 541-549
-
-
Roschewski, M.1
-
78
-
-
84931287940
-
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
-
Kurtz DM, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-3687.
-
(2015)
Blood
, vol.125
, pp. 3679-3687
-
-
Kurtz, D.M.1
-
79
-
-
78049392920
-
How I treat acute myeloid leukemia
-
Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147-3156.
-
(2010)
Blood
, vol.116
, pp. 3147-3156
-
-
Rowe, J.M.1
Tallman, M.S.2
-
80
-
-
0028909393
-
Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules
-
Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-2012.
-
(1995)
Blood
, vol.85
, pp. 2005-2012
-
-
Freeman, S.D.1
Kelm, S.2
Barber, E.K.3
Crocker, P.R.4
-
81
-
-
0036815746
-
Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling
-
Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol 2002;12:609-615.
-
(2002)
Curr Opin Struct Biol
, vol.12
, pp. 609-615
-
-
Crocker, P.R.1
-
82
-
-
0024602797
-
Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
-
Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989;169:1721-1731.
-
(1989)
J Exp Med
, vol.169
, pp. 1721-1731
-
-
Andrews, R.G.1
Singer, J.W.2
Bernstein, I.D.3
-
83
-
-
29444437433
-
Siglecs-the major subfamily of I-type lectins
-
Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006;16:1R-27R.
-
(2006)
Glycobiology
, vol.16
, pp. 1R-27R
-
-
Varki, A.1
Angata, T.2
-
84
-
-
84903122676
-
The past and future of CD33 as therapeutic target in acute myeloid leukemia
-
Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 2014;28:143-153.
-
(2014)
Blood Rev
, vol.28
, pp. 143-153
-
-
Laszlo, G.S.1
Estey, E.H.2
Walter, R.B.3
-
85
-
-
0022806814
-
The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors
-
Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986;68:1030-1035.
-
(1986)
Blood
, vol.68
, pp. 1030-1035
-
-
Andrews, R.G.1
Takahashi, M.2
Segal, G.M.3
Powell, J.S.4
Bernstein, I.D.5
Singer, J.W.6
-
86
-
-
0026594439
-
Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures
-
La Russa VF, et al. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol 1992;20:442-448.
-
(1992)
Exp Hematol
, vol.20
, pp. 442-448
-
-
La Russa, V.F.1
-
87
-
-
30144433084
-
A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing
-
Hernandez-Caselles T, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 2006;79:46-58.
-
(2006)
J Leukoc Biol
, vol.79
, pp. 46-58
-
-
Hernandez-Caselles, T.1
-
88
-
-
18244428964
-
Differences in CD33 intensity between various myeloid neoplasms
-
Jilani I, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002;118:560-566.
-
(2002)
Am J Clin Pathol
, vol.118
, pp. 560-566
-
-
Jilani, I.1
-
89
-
-
84897019168
-
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
-
Krupka C, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123:356-365.
-
(2014)
Blood
, vol.123
, pp. 356-365
-
-
Krupka, C.1
-
90
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
-
(2001)
Nature
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
91
-
-
28844456971
-
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
-
Taussig DC, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005;106:4086-4092.
-
(2005)
Blood
, vol.106
, pp. 4086-4092
-
-
Taussig, D.C.1
-
92
-
-
84859899567
-
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
-
Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012;119:6198-6208.
-
(2012)
Blood
, vol.119
, pp. 6198-6208
-
-
Walter, R.B.1
Appelbaum, F.R.2
Estey, E.H.3
Bernstein, I.D.4
-
93
-
-
84881305790
-
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
-
Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-4860.
-
(2013)
Blood
, vol.121
, pp. 4854-4860
-
-
Petersdorf, S.H.1
-
94
-
-
84859911350
-
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
-
Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-1516.
-
(2012)
Lancet
, vol.379
, pp. 1508-1516
-
-
Castaigne, S.1
-
95
-
-
84897018823
-
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
-
Laszlo GS, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123:554-561.
-
(2014)
Blood
, vol.123
, pp. 554-561
-
-
Laszlo, G.S.1
-
96
-
-
84958748868
-
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE(R) antibody construct AMG 330: reversing a T-cell induced immune escape mechanism
-
[E-pub ahead of print].
-
Krupka C, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE(R) antibody construct AMG 330: reversing a T-cell induced immune escape mechanism. Leukemia 2015 [E-pub ahead of print].
-
(2015)
Leukemia
-
-
Krupka, C.1
-
97
-
-
84938252275
-
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
-
Schnorfeil FM, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 2015;8:93.
-
(2015)
J Hematol Oncol
, vol.8
, pp. 93
-
-
Schnorfeil, F.M.1
-
99
-
-
0034627152
-
Ep-CAM overexpression in breast cancer as a predictor of survival
-
Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-1982.
-
(2000)
Lancet
, vol.356
, pp. 1981-1982
-
-
Gastl, G.1
Spizzo, G.2
Obrist, P.3
Dunser, M.4
Mikuz, G.5
-
100
-
-
4043147142
-
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
-
Spizzo G, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-213.
-
(2004)
Breast Cancer Res Treat
, vol.86
, pp. 207-213
-
-
Spizzo, G.1
-
101
-
-
4143074922
-
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
-
Osta WA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-5824.
-
(2004)
Cancer Res
, vol.64
, pp. 5818-5824
-
-
Osta, W.A.1
-
102
-
-
33750165279
-
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
-
Spizzo G, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-488.
-
(2006)
Gynecol Oncol
, vol.103
, pp. 483-488
-
-
Spizzo, G.1
-
103
-
-
59749103834
-
Nuclear signalling by tumour-associated antigen EpCAM
-
Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-171.
-
(2009)
Nat Cell Biol
, vol.11
, pp. 162-171
-
-
Maetzel, D.1
-
104
-
-
67651003100
-
The emerging role of EpCAM in cancer and stem cell signaling
-
Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69:5627-5629.
-
(2009)
Cancer Res
, vol.69
, pp. 5627-5629
-
-
Munz, M.1
Baeuerle, P.A.2
Gires, O.3
-
105
-
-
67651165121
-
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
-
Amann M, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009;32:452-464.
-
(2009)
J Immunother
, vol.32
, pp. 452-464
-
-
Amann, M.1
-
106
-
-
54849440117
-
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
-
Amann M, et al. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother 2009;58:95-109.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 95-109
-
-
Amann, M.1
-
107
-
-
84867733430
-
A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors
-
Fiedler WM, et al. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J Clin Oncol 2012;30:2504.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2504
-
-
Fiedler, W.M.1
-
108
-
-
74249122446
-
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
-
Osada T, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010;102:124-133.
-
(2010)
Br J Cancer
, vol.102
, pp. 124-133
-
-
Osada, T.1
-
109
-
-
84969406844
-
In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111)
-
Ryan PC, et al. In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111). ALTEX Proc 2012;1:85-87.
-
(2012)
ALTEX Proc
, vol.1
, pp. 85-87
-
-
Ryan, P.C.1
-
110
-
-
84957631975
-
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma
-
TPS3097
-
De Vries E, et al. Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. J Clin Oncol 2015;33:TPS3097.
-
(2015)
J Clin Oncol
, vol.33
-
-
De Vries, E.1
-
111
-
-
67449097665
-
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
-
Lutterbuese R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009;32:341-352.
-
(2009)
J Immunother
, vol.32
, pp. 341-352
-
-
Lutterbuese, R.1
-
112
-
-
78651382134
-
Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
-
Petsch S, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 2011;3:31-37.
-
(2011)
MAbs
, vol.3
, pp. 31-37
-
-
Petsch, S.1
-
113
-
-
84871360414
-
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens
-
Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012;11:2664-2673.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 2664-2673
-
-
Friedrich, M.1
-
114
-
-
84930415352
-
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
-
Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother 2015;64:677-688.
-
(2015)
Cancer Immunol Immunother
, vol.64
, pp. 677-688
-
-
Osada, T.1
Patel, S.P.2
Hammond, S.A.3
Osada, K.4
Morse, M.A.5
Lyerly, H.K.6
-
115
-
-
84969385203
-
®) in human EpCAM-positive tumor bearing mice
-
®) in human EpCAM-positive tumor bearing mice. Eur J Cancer 2014;50:174.
-
(2014)
Eur J Cancer
, vol.50
, pp. 174
-
-
Warnders, F.J.1
-
116
-
-
84920833141
-
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
-
Oberst MD, et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014;6:1571-1584.
-
(2014)
MAbs
, vol.6
, pp. 1571-1584
-
-
Oberst, M.D.1
-
117
-
-
77955433583
-
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
-
Lutterbuese R, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 2010;107:12605-12610.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 12605-12610
-
-
Lutterbuese, R.1
|